Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

M SaigiA McLeer-FlorinE ProsE NadalE BrambillaMontse Sanchez-Cespedes

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2017)

MET activation, by either METex14 mutations or amplification, is characteristic of a subset of early stage NSCLCs and may coexist with ERBB2 amplification. This may have potential therapeutic implications. The presence of METex14 mutations was associated with low levels of MET protein, which may limit the use of total MET immunostaining as a marker for preselecting patients for MET-targeted therapies.

Keyphrases

tyrosine kinase
early stage
end stage renal disease
ejection fraction
chronic kidney disease
nucleic acid
gene expression
lymph node
small molecule
rectal cancer